By deciphering this network of cellular transport, Dr. Shah can target specific molecules to restore normal function and preserve vision in pediatric eye diseases.
Read More
She plans to target a signaling pathway for the resident immune cell of the retina, in order to delay cone degeneration, with the goal of improving long-term rescue following gene therapy. Together, these studies will allow for development of new strategies to extend the therapeutic window in order to treat patients with BCM at all ages (infant to adult), as well as therapy longevity for treatment of BCM.
Read More
Dr. Riaz has developed cells that can serve as an alternative to donor tissue in treating adult animals with corneal edema. The strategy includes treating corneal endothelial edema using differentiated cells in juvenile rabbits and monkeys. The knowledge gained from this project will bring us one step closer to preventing childhood blindness.
Read More
Dr. Pham is investigating the efficacy of CRISPR for treating several cellular models of pediatric ophthalmic diseases, including Leber Hereditary Optic Neuropathy (LHON), Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS), and Leigh syndrome with ophthalmoplegia. Successful demonstration of CRISPR for targeting mitochondrial DNA will open a new therapeutic avenue for these rare and incurable diseases.
Read More
Dr. Oke is developing a mathematical model based on one full year of US births that will predict whether newborn screening could prevent visual impairment in children with retinoblastoma. The result would be earlier access to care even for the most disadvantaged children within and outside of the US.
Read More
Dr. Manohar’s goal is to determine how CHD7 functions to regulate cell type differentiation in the retina, by utilizing single cell transcriptomic and chromatin binding assays in the zebrafish model. Results of these experiments will provide critical information on how CHD7 regulates retinal development, which could lead to development of new therapeutic approaches for the vision impairment associated with CHARGE syndrome.
Read More
He hopes to get fresh insight into the therapeutic approaches for RP and STGD by targeting three different nodes of ceramide metabolism - inhibiting two key enzymes generating ceramide and stimulating AdipoR1 ceramide-degrading activity to lower pathologically increased ceramides.
Read More
Dr. Krusnauskas will use RP1 gene as an example to evaluate the therapeutic potential of twinPE approach for treating inherited retinal degenerations.
Read More
Dr. Jalligampala hopes to refine the Wave1 dose/response curve; define the temporal window of efficacy using the optimal dose and evaluate its safety in intravitreal injections. To do so, she will quantify and compare across treated and untreated conditions how many rods and how much rod function is retained/recovered. The data will define key features of Wave1 administration, and issues relevant to its clinical use.
Read More
Juvenile X-linked retinoschisis is an eye disease that primarily affects male children and causes them to lose vision. In this disease, the connected layers of cells in the eye responsible for forming vision are separated by abnormal, fluid-filled pockets. This is because the function of the RS1 gene is disrupted. This disease can potentially be treated by gene therapy, which involves the delivery of the RS1 gene into the eye using engineered viruses as carriers. However, sometimes, the injections can cause undesirable side effects due to the immune system. Dr. Hsu is investigating the effect of the immune system after treatment in order to better the design of this therapy.
Read More
Dr. Holubowicz is working towards delivery of a prime editor as a purified protein-RNA complex to accomplish precise and efficient repair of a blindness-causing mutant gene. His approach will facilitate the development of therapies that would restore vision after single administration.
Read More
By the end of this project, she will have new in vivo biomarkers for the developmental damage in the retina, which will profoundly impact broader pediatric ophthalmology. This work will represent the first vis-OCT application to pediatric diseases; and the findings of this research can be translated to human studies by using the same technology platform.
Read More
This will lead to improved screening, monitoring, and treatment of inflammation in children, resulting in better long-term vision outcomes and preventing vision loss.
Read More
Dr. Young aims to precisely define the rate of vessel growth in prematurity and ROP, as well as characterize microvascular changes at the edge of ROP, with the goal to provide novel avenues to predict disease.
Read More
We would like to recognize the Grand Commandery of Kentucky for the hard work they have done over these past few years in achieving the goal of 100% Life Sponsorship participation where all Sir Knights of their Grand Commandery have now received a Life Sponsor.
Read More
In this proposal Dr. Chekuri will test a novel gene editing strategy specifically in the retina. Given the speed with which AAV directed gene therapy for retinal disease is moving into the clinic, he is confident that his novel gene editing strategy will open new avenues in the treatment of FD. The studies out lined in the proposal will not only address a critical unmet medical need in FD but will also allow him to uncover the precise mechanism by which retinal ganglion cells are selectively lost in FD. Successful completion of the stated aims will certainly have implications for treating FD.
Read More
Dr. Ali’s long-term goal is to start an independent research laboratory focused on RGC survival; factors identified here will be further investigated in her laboratory as potential gene therapies to maintain RGC health in children suffering from glaucoma.
Read More
To my fellow Sir Knights of the Grand Encampment, I am deeply honored to be called upon once again this year to serve the Knights Templar Eye Foundation as your Chairman for the 56th Annual Voluntary Campaign. I would like to thank Sir Knight David Kussman, our Grand Master and President of the Foundation for giving me the opportunity to serve this Foundation and Templary. We owe all the Sir Knights of the Grand Encampment a sincere thank you for all the donations we received during our the 55th Annual Voluntary campaign.
Read More
Altogether, this project aims to provide important new insights into the regulation of pathologic retinal neovascularization in ROP by pericytes and also the identification of Sema3F as a novel regulator in ROP that could be targeted in patients.
Read More
This work will determine whether SOCS3, which links altered inflammatory responses in stressed photoreceptor cells with neovascularization, is important for neovascular ROP. The proposed research can help understand ROP disease and lead to new disease treatments.
Read More